课题基金 / 基金详情

HHSN261201200021I/HHSN26100007Preclinical In Vitro and In Vivo Development Assays for Cancer Preventative Reagent. Project Title: Effect of Bazedoxifene Either Alone or in Combination with an Aroma

HHSN261201200021I/HHSN26100007Preclinical In Vitro and In Vivo Development Assays for Cancer Preventative Reagent. Project Title: Effect of Bazedoxifene Either Alone or in Combination with an Aroma
HHSN261201200021I/HHSN26100007癌症预防试剂的临床前体外和体内开发测定。
批准号：
8945265
负责人：
CLINTON GRUBBS
金额：
$54.51万
依托单位：
UNIVERSITY OF ALABAMA AT BIRMINGHAM
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
项目状态：
已结题
起止时间：
2014-09-12 至 2016-09-11
来源：
https://reporter.nih.gov/project-details/8945265
关键词：
AnimalsBiological MarkersChemopreventive AgentContractorContractsDataDoseExperimental ModelsFemaleGenerationsHistologicIn VitroLesionMalignant NeoplasmsMammary NeoplasmsMammary TumorigenesisMaximum Tolerated DoseMethodologyMethylnitrosoureaMolecular TargetNitrosourea CompoundsProtocols documentationReagentRouteSelective Estrogen Receptor ModulatorsSignal PathwaySignal TransductionSprague-Dawley RatsTestingTimeTissue Banksanimal age groupassay developmentdesignin vivopreventtumor

项目摘要

项目成果

CLINTON GRUBBS的其他基金

相似基金

相关文献

中文摘要
翻译
本合同旨在评估新的第三代SERM——Bazedoxifene单独或与CE和/或AI联合用于预防n -甲基-n -亚硝基脲（MNU）在雌性雌性Sprague-Dawley大鼠中诱导的乳腺癌。任务将包括优化BZA给药的剂量和时间，以及BZA结合AI的PK谱。
英文摘要
This contract is to assess the new third-generation SERM, Bazedoxifene, alone and in combination with CE and/or an AI, to prevent mammary carcinogenesis induced in virgin female Sprague-Dawley rats by N-methyl-N-nitrosourea (MNU). The tasks will involve optimizing the dose and timing of BZA administration, and PK profile of BZA in combination with the AI.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
TASK ORDER: EVALUATION OF TWO DIFFERENT CLASSES OF COMPOUNDS (STAT3 INHIBITORS AND SERMS) FOR THE PREVENTION OF URINARY BLADDER CANCER
FURTHER DEVELOPMENT OF COLOVAC, A MULTI-ANTIGEN MULTI-PEPTIDE VACCINE, FOR COLON CANCER PREVENTION
IGF::OT::IGF EVALUATION OF AGENTS/PROTOCOLS THAT INHIBIT TWO MAJOR PATHWAYS INVOLVED IN HUMAN URINARY BLADDER CANCER(PI3K, EGFR) AND PROTOCOLS TO REDUCE THEIR TOXICITY
HHSN261201200020I/HHSN26100006 Title: Preclinical In Vitro And In Vivo Screening Assays For Cancer Preventative Reagent Development, Task Order Title: Evaluation on the Prevention by Actoplus/Met (Pi
海外基金